The Multidimensional Fatigue Inventory (MFI) is a commonly used cancer-related fatigue assessment tool. Unlike other fatigue assessments, there are no published minimal clinically important difference (MCID) criteria for the MFI in cancer populations. MCID criteria determine the smallest change in scores that can be regarded as important, allowing clinicians and researchers to interpret the meaning of changes in patient’s fatigue scores. This research aims to improve the clinical utility of the MFI by establishing MCID criteria for the MFI sub-scales in a radiotherapy population.
Materials and methods
Two hundred ten patients undergoing radiotherapy were recruited to a single-centre prospective cohort study. Patients were assessed at three time points, at the start of radiotherapy, the end of radiotherapy and 6 weeks after radiotherapy completion. Assessment consisted of four clinically relevant constructs: (1) treatment impact on fatigue, (2) health-related quality of life, (3) performance status and (4) occupational productivity. These constructs were used as external or anchor-based measures to determine MCIDs for each sub-scale of the MFI.
Multiple MCIDs were identified, each from a different perspective based on the constructs cited. Researchers seeking to use a generic MCID may wish to use a two-point reference for each MFI sub-scale as it was consistent across the pre- and post-radiotherapy comparison and occupational productivity anchors.
MCIDs validated in this study allow better interpretation of changes in MFI sub-scale scores and allow effect size calculations for determining sample size in future studies.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Multidimensional Fatigue Inventory
minimal clinically important difference
Abernethy AP, Shelby-James T, Fazekas BS, Woods D, Currow DC (2005) The Australia-modified Karnofsky Performance Status (AKPS) scale: a revised scale for contemporary palliative care clinical practice [ISRCTN81117481]. BMC Palliat Care 4:7. doi:10.1186/1472-684X-4-7
Ahlberg K, Ekman T, Gaston-Johansson F (2004) Levels of fatigue compared to levels of cytokines and hemoglobin during pelvic radiotherapy: a pilot study. Biol Res Nurs 5:203–210. doi:10.1177/1099800403259500
Ahlberg K, Ekman T, Gaston-Johansson F (2005) The experience of fatigue, other symptoms and global quality of life during radiotherapy for uterine cancer. Int J Nurs Stud 42:377–386. doi:10.1016/j.ijnurstu.2004.07.008
Cella D, Eton DT, Lai J-S, Peterman AH, Merkel DE (2002) Combining anchor and distribution-based methods to derive minimal clinically important differences on the functional assessment of cancer therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage 24:547–561. doi:10.1016/S0885-3924(02)00529-8
Crosby RD, Kolotkin RL, Williams GR (2003) Defining clinically meaningful change in health-related quality of life. J Clin Epidemiol 56:395–407. doi:10.1016/S0895-4356(03)00044-1
Curt GA, Breitbart W, Cella D, Groopman JE, Horning SJ, Itri LM et al (2000) Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist 5:353–360. doi:10.1634/theoncologist.5-5-353
Drummond M, O’Brien B, Stoddart G, Torrance G (1993) Methods for the economic evaluation of health care programmes. Oxford Medical, New York
Ericsson A, Mannerkorpi K (2007) Assessment of fatigue in patients with fibromyalgia and chronic widespread pain. Reliability and validity of the Swedish version of the MFI-20. Disabil Rehabil 29:1665–1670
Furst CJ, Ahsberg E (2001) Dimensions of fatigue during radiotherapy. An application of the multidimensional fatigue inventory. Support Care Cancer 9:355–360. doi:10.1007/s005200100242
Goligher EC, Pouchot J, Brant R, Kherani RB, Avina-Zubieta JA, Lacaille D et al (2008) Minimal clinically important difference for 7 measures of fatigue in patients with systemic lupus erythematosus. J Rheumatol 35:635–642
Hofman M, Ryan JL, Figueroa-Moseley CD, Jean-Pierre P, Morrow GR (2007) Cancer-related fatigue: the scale of the problem. Oncologist 12:4–10. doi:10.1634/theoncologist.12-S1-4
Jaeschke R, Singer J, Guyatt GH (1989) Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 10:407–415. doi:10.1016/0197-2456(89)90005-6
Jean-Pierre P, Figueroa-Moseley CD, Kohli S, Fiscella K, Palesh OG, Morrow GR (2007) Assessment of cancer-related fatigue: implications for clinical diagnosis and treatment. Oncologist 12(Suppl 1):11–21. doi:10.1634/theoncologist.12-S1-11
Jereczek-Fossa BA, Marsiglia HR, Orecchia R (2002) Radiotherapy-related fatigue. Crit Rev Oncol Hematol 41:317–325. doi:10.1016/S1040-8428(01)00143-3
Meek PM, Nail LM, Barsevick A, Schwartz AL, Stephen S, Whitmer K et al (2000) Psychometric testing of fatigue instruments for use with cancer patients. Nurs Res 49:181–190. doi:10.1097/00006199-200007000-00001
Mor V, Laliberte L, Morris JN, Wiemann M (1984) The Karnofsky performance status scale. An examination of its reliability and validity in a research setting. Cancer 53:2002–2007. doi:10.1002/1097-0142(19840501)53:9<2002::AID-CNCR2820530933>3.0.CO;2-W
National Comprehensive Cancer Network (2007) Clinical practice guidelines in oncology: cancer-related fatigue 4. http://www.nccn.org/professionals/physician_gls/PDF/fatigue.pdf. Accessed 20 December 2007
Pickard AS, Neary MP, Cella D (2007) Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes 5:70. doi:10.1186/1477-7525-5-70
Pickard AS, Wilke CT, Lin HW, Lloyd A (2007) Health utilities using the EQ-5D in studies of cancer. Pharmacoeconomics 25:365–384. doi:10.2165/00019053-200725050-00002
Portney L, Watkins M (2009) Foundations of clinical research. Pearson Prentice Hall, Upper Saddle River, pp 619–658
Pouchot J, Kherani RB, Brant R, Lacaille D, Lehman AJ, Ensworth S et al (2008) Determination of the minimal clinically important difference for seven fatigue measures in rheumatoid arthritis. J Clin Epidemiol 61:705–713
Rabin R, de Charro F (2001) EQ-5D: a measure of health status from the EuroQol Group. Ann Med 33:337–343. doi:10.3109/07853890109002087
Rejas J, Pardo A, Ruiz MA (2008) Standard error of measurement as a valid alternative to minimally important difference for evaluating the magnitude of changes in patient-reported outcomes measures. J Clin Epidemiol 61:350–356. doi:10.1016/j.jclinepi.2007.05.011
Sloan J, Symonds T, Vargas-Chanes D, Fridley B (2003) Practical guidelines for assessing significance of health-related quality of life changes in clinical trials. Drug Inf J 37:23–31
Smets EM, Garssen B, Bonke B, De Haes JC (1995) The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res 39:315–325. doi:10.1016/0022-3999(94)00125-O
Smets E, Visser MR, Willems-Groot AF, Garssen B, Oldenburger F, van Tienhoven G et al (1998) Fatigue and radiotherapy: (A) experience in patients undergoing treatment. Br J Cancer 78:899–906
Smets E, Visser MR, Willems-Groot AF, Garssen B, Schuster-Uitterhoeve AL, de Haes JC (1998) Fatigue and radiotherapy: (B) experience in patients 9 months following treatment. Br J Cancer 78:907–912
Strauss B, Brix C, Fischer S, Leppert K, Fuller J, Roehrig B et al (2007) The influence of resilience on fatigue in cancer patients undergoing radiation therapy (RT). J Cancer Res Clin Oncol 133:511–518. doi:10.1007/s00432-007-0195-z
Turriziani A, Mattiucci GC, Montoro C, Ferro M, Maurizi F, Smaniotto D et al (2005) Radiotherapy-related fatigue: incidence and predictive factors. Rays 30:197–203
van Roijen L, Essink-Bot ML, Koopmanschap MA, Bonsel G, Rutten FF (1996) Labor and health status in economic evaluation of health care. The Health and Labor Questionnaire. Int J Technol Assess Health Care 12:405–415
The authors wish to thank the generous funding provided by the Queensland Health Cancer Clinical Network and the Princess Alexandra Hospital Cancer Collaborative Group.
About this article
Cite this article
Purcell, A., Fleming, J., Bennett, S. et al. Determining the minimal clinically important difference criteria for the Multidimensional Fatigue Inventory in a radiotherapy population. Support Care Cancer 18, 307–315 (2010). https://doi.org/10.1007/s00520-009-0653-z
- Cancer-related fatigue
- Minimal clinically important difference
- Multidimensional fatigue inventory
- Anchor-based methods
- Distribution-based methods